Legislative Update: President Trump Signs the One Big Beautiful Bill Act into Law

Topic(s):

Medicaid

On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law. Flanked by Republican leadership on the White House lawn, the President commemorated passage of the massive budget reconciliation package, which includes an extension of the 2017 Tax Cuts and Jobs Act, additional changes to the tax code excluding portions of tipped, overtime, and Social Security income, additional funding for defense, domestic energy production, and border security, and significant cuts to federal benefit programs including Medicaid, CHIP, and the Supplemental Nutrition Assistance Program (SNAP).

Read Analysis

Letters, Statements & Analysis July 3, 2025

AMCP Concerned by Loss of Critical Health Services for Millions of Patients under H.R. 1

H.R. 1 will result in less preventive care and more preventable emergency room visits, increasing costs for everyone across the health care system and threatening hospitals with closure, which will further reduce access to critical care for American patients.

Medicaid

Letters, Statements & Analysis June 27, 2025

Supreme Court Ruling on the Constitutionality of the USPSTF

In Kennedy v. Braidwood Management, Inc., the plaintiffs challenged the constitutionality of the USPSTF, arguing that USPSTF members should be considered “principal officers” under the Appointments Clause and, therefore, must be appointed by the President and confirmed by the Senate.

Legislation & Regulation

Letters, Statements & Analysis June 26, 2025

AMCP Comment Letter on Medicare Drug Price Negotiation Program Draft Guidance

As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.

Quality of Care, Legislation & Regulation, Coverage Parity, Drug Utilization Review (DUR)